<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Haematologica</journal-id><journal-id journal-id-type="iso-abbrev">Haematologica</journal-id><journal-id journal-id-type="pmc-domain-id">820</journal-id><journal-id journal-id-type="pmc-domain">haematol</journal-id><journal-id journal-id-type="publisher-id">HAEMA</journal-id><journal-title-group><journal-title>Haematologica</journal-title></journal-title-group><issn pub-type="ppub">0390-6078</issn><issn pub-type="epub">1592-8721</issn><publisher><publisher-name>Ferrata Storti Foundation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10905095</article-id><article-id pub-id-type="pmcid-ver">PMC10905095.1</article-id><article-id pub-id-type="pmcaid">10905095</article-id><article-id pub-id-type="pmcaiid">10905095</article-id><article-id pub-id-type="pmid">37767566</article-id><article-id pub-id-type="doi">10.3324/haematol.2023.283649</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article - Cell Therapy &amp; Immunotherapy</subject></subj-group></article-categories><title-group><article-title>Lower overall survival in male patients with advanced disease undergoing allogeneic hematopoietic stem cell transplantation is associated with <italic toggle="yes">CYP1B1</italic> Leu432Val polymorphism</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Stute</surname><given-names initials="N">Norbert</given-names></name><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Koldehoff</surname><given-names initials="M">Michael</given-names></name><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="cor1" ref-type="corresp"/></contrib></contrib-group><aff id="aff001"><label>1</label>Department of Bone Marrow Transplantation, West German Cancer Center, <institution>University Hospital of Essen, University of Duisburg-Essen</institution>, Essen, Germany</aff><aff id="aff002"><label>2</label>Third Medical Department with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases and Rheumatology, <institution>Paracelsus Medical University</institution>, Salzburg, Austria</aff><aff id="aff003"><label>3</label>Department of Hygiene and Environmental Medicine, <institution>University Hospital Essen, University of Duisburg-Essen</institution>, Essen, Germany</aff><aff id="aff004"><label>4</label><addr-line>Institute for Laboratory Medicine and Transfusion Medicine</addr-line>, Zotz Klimas, D&#252;sseldorf, <addr-line>Germany</addr-line></aff><author-notes><corresp id="cor1">M. Koldehoff <email>koldehoff@zotzklimas.de</email></corresp><fn><p>
<bold>Disclosures</bold>
</p><p>
<italic toggle="yes">No conflicts of interest to disclose.</italic>
</p></fn><fn><p>
<bold>Contributions</bold>
</p><p>
<italic toggle="yes">NS was responsible for the analysis of data, interpretation of results, and literature research. He performed the statistical analyses, created tables and figures, and wrote the manuscript. MK was responsible for the design of the study and conduct of the research. He obtained funds, designed the laboratory protocol, supervised experiments, and extracted and collected both clinical and lab data. He also revised and edited the manuscript. Both authors approved the final version of the manuscript.</italic>
</p></fn><fn><p>
<bold>Data-sharing statement</bold>
</p><p>
<italic toggle="yes">The data supporting the findings of this study are available upon request from the corresponding author.</italic>
</p></fn></author-notes><pub-date pub-type="epub"><day>28</day><month>9</month><year>2023</year></pub-date><pub-date pub-type="collection"><day>01</day><month>3</month><year>2024</year></pub-date><volume>109</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">456880</issue-id><fpage>799</fpage><lpage>808</lpage><history><date date-type="received"><day>01</day><month>6</month><year>2023</year></date><date date-type="accepted"><day>18</day><month>9</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>28</day><month>09</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>02</day><month>03</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-10-09 14:25:15.503"><day>09</day><month>10</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright&#169; 2024 Ferrata Storti Foundation</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">by-nc 4.0</uri>) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="109799.pdf"/><abstract><p>Human cytochrome P450 1B1 (CYP1B1) is an extrahepatic key enzyme involved in estrogen metabolism, steroid synthesis, and pro-carcinogen activation. In a single-center retrospective study, 382 patients who underwent allogeneic hematopoetic stem cell transplantation and their donors were genotyped for <italic toggle="yes">CYP1B1</italic> C432G polymorphism by reverse transcription polymerase chain reaction. One hundred and sixty-nine patients (44%) were homozygous wild-type (wt) gene CC, 157 (41%) heterozygous CG and 56 (15%) homozygous gene mutated GG. Of interest, mutated <italic toggle="yes">CYP1B1</italic> was more common in male (62%) than in female patients (48%) <italic toggle="yes">P</italic>=0.006, unlike in donors. Five-year estimate for overall survival (OS) was 58&#177;4% (CC) <italic toggle="yes">versus</italic> 48&#177;3% (CG and GG), <italic toggle="yes">P</italic>=0.048. Surprisingly, this difference was only evident in males (<italic toggle="yes">P</italic>=0.024): OS 58&#177;6% <italic toggle="yes">versus</italic> 42&#177;4%, whereas it was virtually absent in females. Importantly, this difference was only evident in male patients with advanced disease (AD) (n=118, <italic toggle="yes">P</italic>=0.002): OS 44&#177;8% (CC) <italic toggle="yes">versus</italic> 32&#177;6% (CG) <italic toggle="yes">versus</italic> 6&#177;6% (GG), whereas it was virtually absent in male patients with early disease. One-year non-relapse mortality in male patients with AD was 8&#177;4% (CC) <italic toggle="yes">versus</italic> 21&#177;5% (CG) <italic toggle="yes">versus</italic> 50&#177;12% (GG), <italic toggle="yes">P</italic>=0.002. Three-year relapse rate in male patients with AD was 31&#177;7% (wt) <italic toggle="yes">versus</italic> 42&#177;6% (mut), <italic toggle="yes">P</italic>=0.04. Multivariate analysis for OS in male patients with AD revealed <italic toggle="yes">CYP1B1</italic> polymorphism as the only prognostic factor: RR 1.78, <italic toggle="yes">P</italic>=0.001. In conclusion, these results suggest that male patients with AD and mutant <italic toggle="yes">CYP1B1</italic> polymorphism have lower OS after allogeneic hematopoetic stem cell transplantation due to a higher non-relapse mortality and a higher relapse rate.</p></abstract><funding-group><funding-statement><bold>Funding</bold>: <italic toggle="yes">This work was supported by a grant from Deutsche Kulturstiftung Essen e.V. - research project (05 045).</italic></funding-statement></funding-group><counts><fig-count count="4"/><table-count count="4"/><equation-count count="0"/><ref-count count="54"/><page-count count="10"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1-1"><title>Introduction</title><p>Hematopoietic stem cell transplantation (HSCT) offers the only cure for many hematological neoplasms; however, the mortality rate remains high. Complications after allogeneic HSCT include relapse, graft-<italic toggle="yes">versus</italic>-host disease (GVHD), graft rejection, organ damage, and infection. The outcome of HSCT is influenced both by clinical and genetic factors. Human leukocyte antigen (HLA) compatibility is a well-known limiting factor for the success of allogeneic HSCT.<sup><xref rid="ref1" ref-type="bibr">1</xref></sup> In addition, genes other than those of the HLA system (both minor HLA and non-HLA antigens including KIR), in particular those that are also polymorphic, have been shown as potential factors affecting the success of HSCT.<sup><xref rid="ref2" ref-type="bibr">2</xref></sup> The polymorphic expression of drug-metabolizing enzymes is one of the major factors which causes interindividual variability in drug metabolism, and thereby in pharmacologic and toxicologic responses. Single nucleotide polymorphisms (SNP) within non-HLA genes that are involved with an individual&#8217;s capability to mount an immune response to infectious pathogens, residual leukemia, alloantigens or genes involved in drug metabolism, have been studied for their association with acute GVHD,<sup><xref rid="ref3" ref-type="bibr">3</xref></sup> host organ function, cancer cells, and immune cells, and thus HSCT outcome.<sup><xref rid="ref4" ref-type="bibr">4</xref></sup> These include chemokines and cytokines,<sup><xref rid="ref5" ref-type="bibr">5</xref></sup> and other predictive biomarkers like <italic toggle="yes">CYP2C19,<sup><xref rid="ref6" ref-type="bibr">6</xref></sup> TLR9, NOD2</italic> and <italic toggle="yes">IL23R,<sup><xref rid="ref7" ref-type="bibr">7</xref></sup> TGFB1,<sup><xref rid="ref8" ref-type="bibr">8</xref></sup></italic> and <italic toggle="yes">NOD2/CARD15.<sup><xref rid="ref9" ref-type="bibr">9</xref>,<xref rid="ref10" ref-type="bibr">10</xref></sup></italic></p><p>Human cytochrome P450 1B1 (CYP1B1) is an extrahepatic key enzyme overexpressed in many tumors. It is involved in the production of reactive metabolites, and in the bioactivation of environmental carcinogens.<sup><xref rid="ref11" ref-type="bibr">11-14</xref></sup> CYP1B1 is also involved in sex hormone and estrogen metabolism, and steroid and lipid synthesis. It specifically catalyzes the 4-hydroxylation of 17&#946;-estradiol into 4-hydroxyestradiol, which enables the formation of free radicals that cause DNA damage through redox cycling from compounds such as hydroquinones.<sup><xref rid="ref15" ref-type="bibr">15</xref></sup> The enzyme is primarily found in the endoplasmatic reticulum, and its gene is located on the human chromosome 2p,<sup><xref rid="ref16" ref-type="bibr">16</xref>,<xref rid="ref17" ref-type="bibr">17</xref></sup> whereas the genes for the HLA system are located on chromosome 6p. The <italic toggle="yes">CYP1B1</italic> gene is transcriptionally activated by polycyclic aromatic hydrocarbons, which act via the dioxin inducible Ah receptor complex.<sup><xref rid="ref18" ref-type="bibr">18</xref></sup></p><p><italic toggle="yes">CYP1B1</italic> is strongly overexpressed in multiple human malignancies<sup><xref rid="ref18" ref-type="bibr">18</xref>,<xref rid="ref19" ref-type="bibr">19</xref></sup> and has been used as a target for cancer chemotherapy<sup><xref rid="ref20" ref-type="bibr">20</xref>,<xref rid="ref21" ref-type="bibr">21</xref></sup> and immunotherapy.<sup><xref rid="ref22" ref-type="bibr">22</xref>,<xref rid="ref23" ref-type="bibr">23</xref></sup> Several anticancer agents interact with CYP1B1,<sup><xref rid="ref20" ref-type="bibr">20</xref>,<xref rid="ref24" ref-type="bibr">24</xref></sup> and CYP1B1 inhibitors have been investigated for their anticancer effects.<sup><xref rid="ref25" ref-type="bibr">25</xref></sup> CYP1B1 is expressed in human lymphocytes, variable and highly inducible,<sup><xref rid="ref26" ref-type="bibr">26</xref></sup> and also in monocytes and macrophages.<sup><xref rid="ref27" ref-type="bibr">27</xref></sup> It plays a role in hematopoietic stem and progenitor cell (HSPC) expansion.<sup><xref rid="ref28" ref-type="bibr">28</xref></sup>
<italic toggle="yes">CYP1B1</italic> is also overexpressed in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), lymphoma, and myeloma.<sup><xref rid="ref29" ref-type="bibr">29</xref>,<xref rid="ref30" ref-type="bibr">30</xref></sup> Methylation of <italic toggle="yes">CYP1B1</italic> was associated with worse overall survival (OS) and disease-free survival in young adults with ALL and correlated with decreased <italic toggle="yes">CYP1B1</italic> expression.<sup><xref rid="ref31" ref-type="bibr">31</xref></sup> Several polymorphisms were identified in the <italic toggle="yes">CYP1B1</italic> gene causing interindividual variability<sup><xref rid="ref32" ref-type="bibr">32</xref>,<xref rid="ref33" ref-type="bibr">33</xref></sup> and being associated with a variety of cancers.<sup><xref rid="ref13" ref-type="bibr">13</xref>,<xref rid="ref34" ref-type="bibr">34</xref>,<xref rid="ref35" ref-type="bibr">35</xref></sup> The <italic toggle="yes">CYP1B1</italic> polymorphism C432G = Leu432Val also called rs1056836 causes an amino acid exchange at codon 432, where the C-allele codes for Leu432 (wild-type [wt]), and the G-allele codes for Val432 (variant). Amongst others, this affects the conversion of estradiol to the carcinogenic metabolite 4-hydroxyestradiol.<sup><xref rid="ref32" ref-type="bibr">32</xref>,<xref rid="ref33" ref-type="bibr">33</xref></sup> Mutant (mut) <italic toggle="yes">CYP1B1</italic> Val432Leu is possibly linked with myeloid leukemia.<sup><xref rid="ref36" ref-type="bibr">36</xref></sup> We hypothesized that altered polymorphic drug metabolism by CYP1B1 in patients who underwent allogeneic HSCT, might influence host organ function, cancer cells and donor immune cells, and thus transplant outcome. The aim of our study was to evaluate whether the Leu432Val (or C432G) polymorphism of CYP1B1 enzyme in patients influences the outcome of allogeneic HSCT, in particular: OS, non-relapse mortality (NRM), relapse of disease, and incidence of GVHD.</p></sec><sec id="sec1-2"><title>Methods</title><sec id="sec2-1"><title>Patients</title><p>We included a total of 382 patients (and donors) for the <italic toggle="yes">CYP1B1</italic> gene polymorphism analysis, who were transplanted at the University Hospital of Essen, Department of Bone amended Declaration of Helsinki. All aspects of this study were approved by the Institutional Review Board on Medical Ethics at the University Hospital of Essen (BO 06-3057), and all patients and donors gave their written informed consent.</p><p>Marrow Transplantation. Patient characteristics are outlined in <xref rid="table001" ref-type="table">Table 1</xref>.</p><p>Selection of patients was performed purely on the basis that genetic material (peripheral blood) from both the recipient and the donor were available. Genotyping was performed without knowledge of clinical data, or outcome of the patients analyzed. This study was conducted in accordance with the</p><table-wrap position="anchor" id="table001" orientation="portrait"><label>Table 1.</label><caption><p>Patient demographics, disease and transplant characteristics.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="109799.tab1.jpg"/></table-wrap></sec><sec id="sec2-2"><title>Early disease <italic toggle="yes">versus</italic> advanced disease</title><p>Early disease (ED): patients with acute leukemia (AL) in first complete remission (CR), chronic myloid leukemia (CML) in first chronic phase, osteomyelofibrosis, severe aplastic anemia, paroxysmal nocturnal hemoglobinuria, hypereosinophilic syndrome, refractory anemia (RA) and refractory anemia with ring sideroblast (RARS) (both untransformed myelodysplastic syndrome [MDS]).</p><p>Advanced disease (AD): patients with AL in partial remission (PR) or second CR, secondary AML, relapsed AL, CML with accelerated phase or blast crisis, refractory anemia with excess blasts (RAEB), chronic myelomonocytic leukemia, transformed MDS, multiple myeloma, non-Hodgkin lymphoma, chronic lymphocytic leukemia stage &#8805;3.</p></sec><sec id="sec2-3"><title>Conditioning regimen and clinical study endpoints</title><p>All protocols and procedures are described in detail in the <italic toggle="yes">Online Supplementary Appendix.</italic></p></sec><sec id="sec2-4"><title>Isolation of genomic DNA</title><p>DNA was prepared from peripheral blood mononuclear cells obtained from the donor and patient before the transplant, using the phenol/chloroform method.<sup><xref rid="ref43" ref-type="bibr">43</xref></sup></p></sec><sec id="sec2-5"><title>Genotyping for <italic toggle="yes">CYP1B1</italic> codon 432 polymorphism</title><p><italic toggle="yes">CYP1B1</italic> Leu432Val polymorphism (rs1056836) was analyzed by a LightCycler (Roche Diagnostics; Mannheim, Germany) protocol using the polymerase chain reaction (PCR) primers and hybridization probes published by Br&#252;ning <italic toggle="yes">et al</italic>.<sup><xref rid="ref44" ref-type="bibr">44</xref></sup> The primers for the PCR (and the hybridization probes) were synthesized by MWG Biotech (Ebersberg, Germany). Polymorphisms of <italic toggle="yes">CYP1B1</italic> at codon 432 were determined by use of the hybridization probe format. The following genotypes were determined by reverse transcription (rt)-PCR: CYP1B*1/*1 = CC (wt), <italic toggle="yes">CYP1B*1/*2</italic> = CG, <italic toggle="yes">CYP1B*2/*2</italic> = GG (homozygous mut). PCR and subsequent melting curve analysis were performed using the LightCycler device and software (Roche Applied Science; Mannheim, Germany). Control samples confirmed by sequencing were included in each run.</p></sec><sec id="sec2-6"><title>Statistical analysis</title><p>Probabilities of OS were calculated using the Kaplan-Meier method.<sup><xref rid="ref45" ref-type="bibr">45</xref></sup> Differences between time-to-event distribution functions were compared by a log-rank test (SPSS).<sup><xref rid="ref46" ref-type="bibr">46</xref></sup> Cumulative incidence was used to estimate the endpoints of NRM, relapse and GVHD to accommodate for competing risks (R statistic).<sup><xref rid="ref47" ref-type="bibr">47</xref></sup> Relapse and NRM were analyzed as competing risks.<sup><xref rid="ref48" ref-type="bibr">48</xref></sup> Combined data are shown as mean &#177; standard error. In order to study acute and chronic GVHD, we considered relapse and death to be competing events. Comparisons between categorical covariates were conducted using the &#967;<sup><xref rid="ref2" ref-type="bibr">2</xref></sup> test where appropriate. <italic toggle="yes">P</italic> values are always two-sided. A Cox proportional hazards model was used for multivariate regression to evaluate the prognostic significance of different covariates on the endpoints of OS, NRM, and relapse. Covariates analyzed - see the <italic toggle="yes">Online Supplementary Appendix</italic>. All interactions between patient sex, AD and other covariates were tested. Relative risk (RR) estimates and their 95% confidence intervals (95% CI) were derived from Cox regression after adjustment for all other covariates in the model. Statistics Software used are presented in the <italic toggle="yes">Online Supplementary Appendix</italic>.</p></sec></sec><sec id="sec1-3"><title>Results</title><sec id="sec2-7"><title><italic toggle="yes">CYP1B1</italic> genetic polymorphism in patients and donors</title><p>Among recipients (R) 169 (44%) were genotyped as homozygous wt gene CC, 157 (41%) as heterozygous genotype CG, and 56 (15%) had the homozygous gene mutation GG. As shown in <xref rid="table002" ref-type="table">Table 2</xref>, regarding demographic and transplant characteristics, there was no difference between the three <italic toggle="yes">CYP1B1</italic> C432G polymorphism groups CC, CG and GG in male patients with AD. With exception to age group &gt;50 years, where there appeared to be a higher percentage of wt R SNP. The same holds true when looking at all male patients and the patient cohort overall (<italic toggle="yes">data not shown</italic>). Interestingly, male R were more likely to have the mut SNP compared to female R (62% <italic toggle="yes">vs.</italic> 48%), whereas the wt SNP was more common in females (52% <italic toggle="yes">vs.</italic> 38%), <italic toggle="yes">P</italic>=0.006 (x<sup><xref rid="ref2" ref-type="bibr">2</xref></sup>), see <xref rid="table003" ref-type="table">Table 3A</xref>. This difference was even more pronounced in AD: the prevalence of mut SNP in male R was 67% <italic toggle="yes">versus</italic> 50% in female R.</p><table-wrap position="anchor" id="table002" orientation="portrait"><label>Table 2.</label><caption><p>Male patients with advanced disease - demographic and transplant characteristics (N=118).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="109799.tab2.jpg"/></table-wrap><p>Among donors (D) 167 (44%) were genotyped as homozygous wt gene CC, 162 (42%) as heterozygous genotype CG, and 53 (14%) had the homozygous gene mutation GG. Calculated genotype frequencies were comparable to the R group. Within the donor group however, there was no sex difference in distribution between wt and mut SNP, as shown in <xref rid="table003" ref-type="table">Table 3B</xref>, in contrast to the R group. Our data with donor <italic toggle="yes">CYP1B1</italic> polymorphism or D SNP yielded interesting results. However, D SNP data did not influence the outcome results presented in this paper. Due to clarity and space constraints, they are not included here.</p><p>Across all patients with wt R SNP (n=169), 52% of women, and 51% of men had AD (<italic toggle="yes">P</italic>=0.843). Whereas across all patients with mut R SNP (n=213), 56% of women, and 62% of men had AD (<italic toggle="yes">P</italic>=0.351). Of all male patients (n=204), mut R SNP was 56% in ED, and 67% in AD (<italic toggle="yes">P</italic>=0.105). Whereas of all female patients (n=178), mut R SNP was 46% in ED, and 50% in AD (<italic toggle="yes">P</italic>=0.626).</p></sec><sec id="sec2-8"><title>Overall survival</title><p>Across all patients (n=382) the 5-year estimate for OS was 58&#177;4% for the CC group, 50&#177;4% for the CG, and 46&#177;7% for the GG group (<italic toggle="yes">P</italic>=0.141), whereas it was 58&#177;4% for wt R SNP, and 48&#177;3% for the mut R SNP (CG and GG combined) (<italic toggle="yes">P</italic>=0.048). Multivariate analysis was performed. In all patients the following factors available at transplant influenced the OS: AD (RR 2.70; 95% CI: 1.94-3.77; <italic toggle="yes">P</italic>&lt;0.001), mismatch donor (RR 1.64; 95% CI: 1.19-2.27; <italic toggle="yes">P</italic>=0.003), and age &gt;40 years (RR 1.54; 95% CI: 1.16-2.06; <italic toggle="yes">P</italic>=0.003), and R SNP (RR 1.22; 95% CI: 1.01-1.49; <italic toggle="yes">P</italic>=0.044).</p><p>Importantly, this difference was evident especially in male patients (n=204) where the group with <italic toggle="yes">CYP1B1</italic> mutations did significantly worse: 5-year OS was 58&#177;6% <italic toggle="yes">versus</italic> 44&#177;5% <italic toggle="yes">versus</italic> 37&#177;9% (<italic toggle="yes">P</italic>=0.062) (<xref rid="fig001" ref-type="fig">Figure 1A</xref>), whereas it was 58&#177;6% for wt R SNP <italic toggle="yes">versus</italic> 42&#177;4% for mut R SNP (<italic toggle="yes">P</italic>=0.024). In sharp contrast, OS of female patients was almost identical between the three groups (5-year OS: 58&#177;5% <italic toggle="yes">vs.</italic> 58&#177;6% <italic toggle="yes">vs.</italic> 58&#177;10%) (<xref rid="fig001" ref-type="fig">Figure 1B</xref>). Multivariate analysis was performed. In male patients only the following factors available at transplant influenced OS: AD (RR 2.52; 95% CI: 1.59-4.00; <italic toggle="yes">P</italic>&lt;0.001), R SNP (RR 1.46; 95% CI: 1.12-1.91; <italic toggle="yes">P</italic>=0.005), and age &gt;40 years (RR 1.50; 95% CI: 1.03-2.19; <italic toggle="yes">P</italic>=0.034).</p><p>Interestingly, this difference in survival rate was observed primarily in male patients with AD (n=118), where the group with <italic toggle="yes">CYP1B1</italic> mutations did significantly worse: their 5-year OS was 44&#177;8% <italic toggle="yes">versus</italic> 32&#177;6% <italic toggle="yes">versus</italic> 6&#177;6% (<italic toggle="yes">P</italic>=0.002) (<xref rid="fig002" ref-type="fig">Figure 2A</xref>). In contrast, regarding male patients with ED, OS was almost identical between the three groups (5-year OS: 74&#177;7% <italic toggle="yes">vs.</italic> 69&#177;8% <italic toggle="yes">vs.</italic> 69&#177;12%) 95% CI: 0.16-0.89; <italic toggle="yes">P</italic>=0.026) with PBSC being associated with a lower relapse rate.</p><table-wrap position="anchor" id="table003" orientation="portrait"><label>Table 3.</label><caption><p><italic toggle="yes">CYP1B1</italic> polymorphism (Leu432Val) of recipients (A) and donors (B), N=382.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="109799.tab3.jpg"/></table-wrap><p>(<xref rid="fig002" ref-type="fig">Figure 2B</xref>). Multivariate analysis was performed (<xref rid="table004" ref-type="table">Table 4</xref>). In male patients with AD, only the following factor available at transplant influenced OS: R SNP with RR 1.78; 95% CI: 1.25-2.52; <italic toggle="yes">P</italic>=0.001.</p></sec><sec id="sec2-9"><title>Non-relapse mortality</title><p>One-year estimate for NRM in male patients with AD was 8&#177;4% for wt/wt <italic toggle="yes">versus</italic> 21&#177;5% for mut/wt <italic toggle="yes">versus</italic> 50&#177;12% for mut/mut <italic toggle="yes">CYP1B1</italic> R SNP (<italic toggle="yes">P</italic>=0.002) (<xref rid="fig003" ref-type="fig">Figure 3A</xref>). In contrast, there was no difference in the outcome concerning male patients with ED (NRM 13% <italic toggle="yes">vs.</italic> 13% <italic toggle="yes">vs.</italic> 19%) (<xref rid="fig003" ref-type="fig">Figure 3B</xref>). Multivariate analysis was performed (<xref rid="table004" ref-type="table">Table 4</xref>). In male patients with AD, only the following factor influenced NRM: <italic toggle="yes">CYP1B1</italic> R SNP (RR 1.98; 95% CI: 1.21-3.25; <italic toggle="yes">P</italic>=0.007). Causes of death (n=15) in the GG group (n=16) of male patients with AD were: relapse n=6, sepsis n=4, invasive fungal infection n=3, and veno-occlusive disease n=2 patients. When looking at the R SNP group GG in male patients with AD, there was no pattern with regards to clinical features (see <xref rid="table002" ref-type="table">Table 2</xref>), other outcomes or causes of death compared to group CG and group CC. Relapse and infections were a common cause of death.</p></sec><sec id="sec2-10"><title>Occurrence of relapse</title><p>When looking at relapse, <italic toggle="yes">CYP1B1</italic> genetic polymorphism in patients (R SNP) at first did not seem to make a difference in either sex. However, in male patients with AD (n=118), mut R SNP was associated with more relapses at 3 years than wt R SNP: 31&#177;7% <italic toggle="yes">versus</italic> 43&#177;6% <italic toggle="yes">versus</italic> 38&#177;12% (<italic toggle="yes">P</italic>=0.08) (<xref rid="fig004" ref-type="fig">Figure 4A</xref>). When combining wt/mut and mut/ mut the numbers were 31&#177;7% <italic toggle="yes">versus</italic> 42&#177;6% (<italic toggle="yes">P</italic>=0.04). In contrast, male patients with ED did not show this phenomenon (relapse 24% <italic toggle="yes">vs.</italic> 16% <italic toggle="yes">vs.</italic> 19%) (<xref rid="fig004" ref-type="fig">Figure 4B</xref>). This was confirmed by multivariate analysis in male patients with AD (<xref rid="table004" ref-type="table">Table 4</xref>) where R SNP was the strongest predictor for relapse (RR 1.92; 95% CI: 1.21-3.07; <italic toggle="yes">P</italic>=0.006), with mut R SNP performing worse, and graft type (RR 0.38;</p><fig position="anchor" id="fig001" orientation="portrait"><label>Figure 1.</label><caption><p><bold>Overall survival estimate by <italic toggle="yes">CYP1B1</italic> polymorphism.</bold> (A) Male patients (N=204): patients with mutant (mut) recipient single nucleotide polymorphism (R SNP) (wt/mut and mut/mut) had lower overall survival (OS) than patients with wild-type (wt) R SNP (wt/wt). (B) Female patients (N=178) displaying no difference (not significant [NS]). R SNP here <italic toggle="yes">CYP1B1</italic> C432G polymorphism CC, CG and GG. HSCT: hematopoietic stem cell transplantation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="109799.fig1.jpg"/></fig><fig position="anchor" id="fig002" orientation="portrait"><label>Figure 2.</label><caption><p><bold>Overall survival estimate in male patients by <italic toggle="yes">CYP1B1</italic> polymorphism.</bold> (A) Male patients with advanced disease (N=118):</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="109799.fig2.jpg"/></fig><fig position="anchor" id="fig003" orientation="portrait"><label>Figure 3.</label><caption><p><bold>Non-relapse mortality estimate in male patients by <italic toggle="yes">CYP1B1</italic> polymorphism.</bold> (A) Male patients with advanced disease (N=118): male patients with mutant (mut) recipient single nucleotide polymorphism (R SNP) had a higher non-relapse mortality (NRM) than those with wild-type (wt) R SNP. (B) Male patients with early disease (N=86) displaying no difference (not significant [NS]). HSCT: hematopoietic stem cell transplantation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="109799.fig3.jpg"/></fig><fig position="anchor" id="fig004" orientation="portrait"><label>Figure 4.</label><caption><p><bold>Relapse estimate in male patients by <italic toggle="yes">CYP1B1</italic> polymorphism.</bold> (A) Male patients with advanced disease (N=118). Male patients with mutant (mut) recipient single nucleotide polymorphism (R SNP) had a higher relapse rate than those with wild-type (wt) R SNP. (B) Male patients with early disease (N=86) displaying no difference (not significant [NS]). HSCT: hematopoietic stem cell transplantation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="109799.fig4.jpg"/></fig></sec><sec id="sec2-11"><title>Acute and chronic graft-<italic toggle="yes">versus</italic>-host disease</title><p>In male patients with AD (n=118) the estimated incidence of acute GVHD, grade 3-4 on day 30 post HSCT was 3&#177;3% <italic toggle="yes">versus</italic> 19&#177;6% <italic toggle="yes">versus</italic> 40&#177;14% for R SNP (<italic toggle="yes">P</italic>=0.177). Whereas for male patients with early disease it was 12% <italic toggle="yes">versus</italic> 13% <italic toggle="yes">versus</italic> 7% (<italic toggle="yes">P</italic>=0.633). Although displaying a trend, the numbers were relatively small and not significant. R SNP was also not significant in multivariate analysis for severe acute GVHD. The incidence of chronic GVHD (all stages) was similar in the three R subgroups (R SNP), with 64% in CC, 60% in CG, and 44% in GG (&#967;<sup><xref rid="ref2" ref-type="bibr">2</xref></sup>, P=0.367) in male patients with AD. R SNP was also not significant in multivariate analysis for all stages of chronic GVHD.</p><p>CYP1B1 is not involved in metabolism of immunosuppressants like cyclosporine, and there was no difference observed between the three subgroups of R SNP when comparing cyclosporine or cortisone doses upon discharge.</p><p>For the role of sex mismatch on outcome please see the <italic toggle="yes">Online Supplementary Appendix</italic>.</p></sec><sec id="sec2-12"><title>Engraftment, kidney and liver toxicity</title><p>For 198 of 382 patients (52%) additional data was available. This was an unselected group. Male patients with AD, 57 of 198 (29%) displayed no significant difference in engraftment of neutrophils or thrombocyytes between wt and mut R SNP. We also evaluated the maximum creatinine and bilirubin values after transplant. While there was a tendency towards higher mean (not median) creatinine and bilirubin values in patients with mut R SNP, this difference was small and by no means significant.</p></sec></sec><sec id="sec1-4"><title>Discussion</title><p>In this retrospective single-center study we evaluated the influence of <italic toggle="yes">CYP1B1</italic> polymorphism (Leu432Val) on the clinical outcome after allogeneic HSCT in adult patients. We found that mut SNP is associated with lower OS in male patients with AD due to increased non-relapse mortality, and a higher relapse rate after HSCT. This outcome difference in male patients is not explained by other prognostic factors available at time of transplant. In contrast, this association has not been seen in male patients with ED or in female patients. Of note, the above has been found in a primarily myeloablative setting.</p><p>Interestingly, male patients were more likely to have the mut SNP of <italic toggle="yes">CYP1B1</italic> compared to female patients (62% <italic toggle="yes">vs</italic>. 48%). However, in contrast to the R group (which had hematological cancer - therefore, had also been exposed to anticancer drugs and radiation), there was no sex difference in distribution between wt and mut SNP within the donor group. Calculated Leu432Val (or C432G) genotype frequencies of <italic toggle="yes">CYP1B1</italic> did not differ much from that reported earlier for Caucasians: CC 37%, CG 46% and GG 17%.<sup><xref rid="ref44" ref-type="bibr">44</xref>,<xref rid="ref50" ref-type="bibr">50</xref></sup></p><p>It could therefore be postulated that men with mut SNP have a higher risk of hematological cancer, or are more likely to relapse post induction and consolidation therapy (and thus become transplant candidates more often) than men with wt SNP. This conclusion is corroborated by Tang <italic toggle="yes">et al</italic>.<sup><xref rid="ref51" ref-type="bibr">51</xref></sup> who found that among Caucasians 34% of men with prostate cancer were homozygous for the Val432 polymorphism (or GG in other words), while only 12% of matched control subjects had this genotype. Also by Fritsche <italic toggle="yes">et al</italic>.<sup><xref rid="ref50" ref-type="bibr">50</xref></sup> who reported that genotypes heterozygous and homozygous for the Val432 polymorphism (i.e., CG and GG or mut SNP) were more frequent in patients with colorectal cancer compared to controls.</p><table-wrap position="anchor" id="table004" orientation="portrait"><label>Table 4.</label><caption><p>Results of multivariate analysis for main outcomes after hematopoietic stem cell transplantation - male patients with advanced disease only (N=118).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="109799.tab4.jpg"/></table-wrap><p>Of interest, even though wt SNP was more common in female patients, it does not appear to be associated with a better outcome. Whereas mut SNP appears to have a clear negative effect in men with AD. Female patients with mut SNP seem to have a better outcome than their male counterparts. It could be speculated that this is due to the presence of estrogens. Sissung <italic toggle="yes">et al</italic>.<sup><xref rid="ref52" ref-type="bibr">52</xref></sup> made a similar observation in male patients with prostate cancer: patients with <italic toggle="yes">CYP1B1*3</italic> polymorphic variant (L432V) GG had a decreased OS after docetaxel-based therapies compared with individuals carrying at least one copy of the <italic toggle="yes">CYP1B1*1 (</italic>allele CC or CG).</p><p>NRM was higher in male patients with mut SNP compared to male patients with wt SNP in the AD setting, whereas this difference did not show at all in female patients. An explanation for the NRM increase in male patients with mut SNP could be a higher rate of organ toxicity or more infections due to chemotherapy, radiotherapy or immunotherapy.</p><p>Relapse was higher in male patients with AD for mut SNP compared to wt SNP. This could be due to a poor response of cancer cells with mut SNP to chemotherapy, radiotherapy, and immunotherapy, thus leading to a higher relapse rate in patients with AD.</p><p>Of note, most patients analyzed received myeloablative transplants in the years 1993-2006, median 2002. The field of transplantation has changed over the years due to advances in donor selection and supportive care, i.e., infection disease and GVHD control, resulting in improved survival.</p><p>The sex differences observed in this study comparing wt and mut SNP in recipients were striking. So far, sex differences in outcome after allogeneic HSCT have not been reported with the exception of increased rates of chronic GVHD for female donors and male recipients.<sup><xref rid="ref53" ref-type="bibr">53</xref></sup> T cells of female donors specific for minor histocompatibility antigens encoded by genes on chromosome Y may contribute to GVHD, graft rejection, and graft-<italic toggle="yes">versus</italic>-leukemia effects in hematological malignancies.<sup><xref rid="ref54" ref-type="bibr">54</xref></sup></p><p>In conclusion, our retrospective single-center cohort study provides strong evidence that male patients with mut genetic polymorphism of <italic toggle="yes">CYP1B1</italic> have a lower OS in AD after HSCT, and that this is due to a higher NRM and relapse rate.</p><p>Genotyping for <italic toggle="yes">CYP1B1</italic> C432G polymorphism might therefore help identify patients with higher risk for allogeneic HSCT in the future, and may perhaps also explain some sex differences in outcome. Validation of the role of <italic toggle="yes">CYP1B1</italic> C432G polymorphism in a prosppective study or confirmation in an independent cohort are warranted before any clinical conclusions are drawn. We also suggest further <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> studies on hematological cancers and lymphocytes regarding the role of <italic toggle="yes">CYP1B1</italic> and its Leu432Val polymorphism.</p></sec><sec sec-type="supplementary-material" id="sec1"><title>Supplementary Material</title><supplementary-material id="SD1" position="float" content-type="local-data" orientation="portrait"><label>Supplementary Appendix</label><caption><p>
<fig id="d66e823" position="anchor" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="2023.283649_STUTE_SUPPL.pdf" position="float" orientation="portrait"/></fig>
</p></caption></supplementary-material></sec></body><back><ack><title>Acknowledgments</title><p>
<italic toggle="yes">We thank Christiane Schary, Melanie Kroll, Silke Gottwald, and Ines Riepenhoff (all Essen, Germany) for their excellent technical assistance with PCR analyses. We also wish to thank patients and donors who participated in this study, as well as our colleagues, and the entire medical team at the BMT Center in Essen, especially Prof. Dr. Ahmet H. Elmaagacli. The EBMT statistics course in Leiden 2018 was very beneficial for implementing R. As a native English speaker Rachael Mellor assisted with grammar.</italic>
</p></ack><ref-list><title>References</title><ref id="ref1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Klein</surname><given-names>J</given-names></name><name name-style="western"><surname>Haagenson</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>High-resolution donorrecipient HLA matching contributes to the success of unrelated donor marrow transplantation</article-title>. <source>Blood</source>. <year>2007</year>;<volume>110</volume>(<issue>13</issue>):<fpage>4576</fpage>-<lpage>4583</lpage>.<pub-id pub-id-type="pmid">17785583</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2007-06-097386</pub-id></mixed-citation></ref><ref id="ref2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dickinson</surname><given-names>AM</given-names></name><name name-style="western"><surname>Norden</surname><given-names>J.</given-names></name></person-group><article-title>Non-HLA genomics: does it have a role in predicting haematopoietic stem cell transplantation outcome?</article-title><source>Int J Immunogenet</source>. <year>2015</year>;<volume>42</volume>(<issue>4</issue>):<fpage>229</fpage>-<lpage>238</lpage>.<pub-id pub-id-type="pmid">26010044</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/iji.12202</pub-id></mixed-citation></ref><ref id="ref3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chien</surname><given-names>JW</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>XC</given-names></name><name name-style="western"><surname>Fan</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Evaluation of published single nucleotide polymorphisms associated with acute GVHD</article-title>. <source>Blood</source>. <year>2012</year>;<volume>119</volume>(<issue>22</issue>):<fpage>5311</fpage>-<lpage>5319</lpage>.<pub-id pub-id-type="pmid">22282500</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2011-09-371153</pub-id><pub-id pub-id-type="pmcid">PMC3369619</pub-id></mixed-citation></ref><ref id="ref4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansen</surname><given-names>JA</given-names></name><name name-style="western"><surname>Chien</surname><given-names>JW</given-names></name><name name-style="western"><surname>Warren</surname><given-names>EH</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>LP</given-names></name><name name-style="western"><surname>Martin</surname><given-names>PJ</given-names></name></person-group>. <article-title>Defining genetic risk for graft-versus-host disease and mortality following allogeneic hematopoietic stem cell transplantation</article-title>. <source>Curr Opin Hematol</source>. <year>2010</year>;<volume>17</volume>(<issue>6</issue>):<fpage>483</fpage>-<lpage>492</lpage>.<pub-id pub-id-type="pmid">20827186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MOH.0b013e32833eb770</pub-id><pub-id pub-id-type="pmcid">PMC3177530</pub-id></mixed-citation></ref><ref id="ref5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loeffler</surname><given-names>J</given-names></name><name name-style="western"><surname>Ok</surname><given-names>M</given-names></name><name name-style="western"><surname>Morton</surname><given-names>OC</given-names></name><name name-style="western"><surname>Mezger</surname><given-names>M</given-names></name><name name-style="western"><surname>Einsele</surname><given-names>H.</given-names></name></person-group><article-title>Genetic polymorphisms in the cytokine and chemokine system: their possible importance in allogeneic stem cell transplantation</article-title>. <source>Curr Top Microbiol Immunol</source>. <year>2010</year>;<volume>341</volume>:<fpage>83</fpage>-<lpage>96</lpage>.<pub-id pub-id-type="pmid">20397074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/82_2010_22</pub-id></mixed-citation></ref><ref id="ref6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elmaagacli</surname><given-names>AH</given-names></name><name name-style="western"><surname>Koldehoff</surname><given-names>M</given-names></name><name name-style="western"><surname>Steckel</surname><given-names>NK</given-names></name><name name-style="western"><surname>Trenschel</surname><given-names>R</given-names></name><name name-style="western"><surname>Ottinger</surname><given-names>H</given-names></name><name name-style="western"><surname>Beelen</surname><given-names>DW</given-names></name></person-group>. <article-title>Cytochrome P450 2C19 loss-of-function polymorphism is associated with an increased treatment-related mortality in patients undergoing allogeneic transplantation</article-title>. <source>Bone Marrow Transplant</source>. <year>2007</year>;<volume>40</volume>(<issue>7</issue>):<fpage>659</fpage>-<lpage>664</lpage>.<pub-id pub-id-type="pmid">17680025</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.bmt.1705786</pub-id></mixed-citation></ref><ref id="ref7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elmaagacli</surname><given-names>AH</given-names></name><name name-style="western"><surname>Steckel</surname><given-names>N</given-names></name><name name-style="western"><surname>Ditschkowski</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Toll-like receptor 9, NOD2 and IL23R gene polymorphisms influenced outcome in AML patients transplanted from HLA-identical sibling donors</article-title>. <source>Bone Marrow Transplant</source>. <year>2011</year>;<volume>46</volume>(<issue>5</issue>):<fpage>702</fpage>-<lpage>708</lpage>.<pub-id pub-id-type="pmid">20622911</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/bmt.2010.166</pub-id></mixed-citation></ref><ref id="ref8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arrieta-Bolanos</surname><given-names>E</given-names></name><name name-style="western"><surname>Mayor</surname><given-names>NP</given-names></name><name name-style="western"><surname>Marsh</surname><given-names>SG</given-names></name><etal/></person-group>. <article-title>Polymorphism in TGFB1 is associated with worse non-relapse mortality and overall survival after stem cell transplantation with unrelated donors</article-title>. <source>Haematologica</source>. <year>2016</year>;<volume>101</volume>(<issue>3</issue>):<fpage>382</fpage>-<lpage>390</lpage>.<pub-id pub-id-type="pmid">26611472</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3324/haematol.2015.134999</pub-id><pub-id pub-id-type="pmcid">PMC4815730</pub-id></mixed-citation></ref><ref id="ref9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holler</surname><given-names>E</given-names></name><name name-style="western"><surname>Rogler</surname><given-names>G</given-names></name><name name-style="western"><surname>Herfarth</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation</article-title>. <source>Blood</source>. <year>2004</year>;<volume>104</volume>(<issue>3</issue>):<fpage>889</fpage>-<lpage>894</lpage>.<pub-id pub-id-type="pmid">15090455</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2003-10-3543</pub-id></mixed-citation></ref><ref id="ref10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elmaagacli</surname><given-names>AH</given-names></name><name name-style="western"><surname>Koldehoff</surname><given-names>M</given-names></name><name name-style="western"><surname>Hindahl</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Mutations in innate immune system NOD2/CARD 15 and TLR-4 (Thr399Ile) genes influence the risk for severe acute graft-versus-host disease in patients who underwent an allogeneic transplantation</article-title>. <source>Transplantation</source>. <year>2006</year>;<volume>81</volume>(<issue>2</issue>):<fpage>247</fpage>-<lpage>254</lpage>.<pub-id pub-id-type="pmid">16436969</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.tp.0000188671.94646.16</pub-id></mixed-citation></ref><ref id="ref11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#8217;Uva</surname><given-names>G</given-names></name><name name-style="western"><surname>Baci</surname><given-names>D</given-names></name><name name-style="western"><surname>Albini</surname><given-names>A</given-names></name><name name-style="western"><surname>Noonan</surname><given-names>DM</given-names></name></person-group>. <article-title>Cancer chemoprevention revisited: cytochrome P450 family 1B1 as a target in the tumor and the microenvironment</article-title>. <source>Cancer Treat Rev</source>. <year>2018</year>;<volume>63</volume>:<fpage>1</fpage>-<lpage>18</lpage>.<pub-id pub-id-type="pmid">29197745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ctrv.2017.10.013</pub-id></mixed-citation></ref><ref id="ref12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>X</given-names></name><name name-style="western"><surname>Feng</surname><given-names>S.</given-names></name></person-group><article-title>Role of metobolic enzymes P450 (CYP) on activating procarcinogen and their polymorphisms on the risk of cancers</article-title>. <source>Curr Drug Metab</source>. <year>2015</year>;<volume>16</volume>(<issue>10</issue>):<fpage>850</fpage>-<lpage>863</lpage>.<pub-id pub-id-type="pmid">26652254</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/138920021610151210164501</pub-id></mixed-citation></ref><ref id="ref13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sissung</surname><given-names>TM</given-names></name><name name-style="western"><surname>Price</surname><given-names>DK</given-names></name><name name-style="western"><surname>Sparreboom</surname><given-names>A</given-names></name><name name-style="western"><surname>Figg</surname><given-names>WD</given-names></name></person-group>. <article-title>Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention</article-title>. <source>Mol Cancer Res</source>. <year>2006</year>;<volume>4</volume>(<issue>3</issue>):<fpage>135</fpage>-<lpage>150</lpage>.<pub-id pub-id-type="pmid">16547151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1541-7786.MCR-05-0101</pub-id></mixed-citation></ref><ref id="ref14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimada</surname><given-names>T</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>CL</given-names></name><name name-style="western"><surname>Yamazaki</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1</article-title>. <source>Cancer Res</source>. <year>1996</year>;<volume>56</volume>(<issue>13</issue>):<fpage>2979</fpage>-<lpage>2984</lpage>.<pub-id pub-id-type="pmid">8674051</pub-id></mixed-citation></ref><ref id="ref15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayes</surname><given-names>CL</given-names></name><name name-style="western"><surname>Spink</surname><given-names>DC</given-names></name><name name-style="western"><surname>Spink</surname><given-names>BC</given-names></name><name name-style="western"><surname>Cao</surname><given-names>JQ</given-names></name><name name-style="western"><surname>Walker</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Sutter</surname><given-names>TR</given-names></name></person-group>. <article-title>17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1996</year>;<volume>93</volume>(<issue>18</issue>):<fpage>9776</fpage>-<lpage>9781</lpage>.<pub-id pub-id-type="pmid">8790407</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.93.18.9776</pub-id><pub-id pub-id-type="pmcid">PMC38505</pub-id></mixed-citation></ref><ref id="ref16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sutter</surname><given-names>TR</given-names></name><name name-style="western"><surname>Tang</surname><given-names>YM</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>CL</given-names></name><etal/></person-group>. <article-title>Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2</article-title>. <source>J Biol Chem</source>. <year>1994</year>;<volume>269</volume>(<issue>18</issue>):<fpage>13092</fpage>-<lpage>13099</lpage>.<pub-id pub-id-type="pmid">8175734</pub-id></mixed-citation></ref><ref id="ref17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>YM</given-names></name><name name-style="western"><surname>Wo</surname><given-names>YY</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Isolation and characterization of the human cytochrome P450 CYP1B1 gene</article-title>. <source>J Biol Chem</source>. <year>1996</year>;<volume>271</volume>(<issue>45</issue>):<fpage>28324</fpage>-<lpage>28330</lpage>.<pub-id pub-id-type="pmid">8910454</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.271.45.28324</pub-id></mixed-citation></ref><ref id="ref18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murray</surname><given-names>GI</given-names></name><name name-style="western"><surname>Melvin</surname><given-names>WT</given-names></name><name name-style="western"><surname>Greenlee</surname><given-names>WF</given-names></name><name name-style="western"><surname>Burke</surname><given-names>MD</given-names></name></person-group>. <article-title>Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1</article-title>. <source>Annu Rev Pharmacol Toxicol</source>. <year>2001</year>;<volume>41</volume>:<fpage>297</fpage>-<lpage>316</lpage>.<pub-id pub-id-type="pmid">11264459</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev.pharmtox.41.1.297</pub-id></mixed-citation></ref><ref id="ref19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murray</surname><given-names>GI</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>MC</given-names></name><name name-style="western"><surname>McFadyen</surname><given-names>MC</given-names></name><etal/></person-group>. <article-title>Tumor-specific expression of cytochrome P450 CYP1B1</article-title>. <source>Cancer Res</source>. <year>1997</year>;<volume>57</volume>(<issue>14</issue>):<fpage>3026</fpage>-<lpage>3031</lpage>.<pub-id pub-id-type="pmid">9230218</pub-id></mixed-citation></ref><ref id="ref20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McFadyen</surname><given-names>MC</given-names></name><name name-style="western"><surname>Melvin</surname><given-names>WT</given-names></name><name name-style="western"><surname>Murray</surname><given-names>GI</given-names></name></person-group>. <article-title>Cytochrome P450 enzymes: novel options for cancer therapeutics</article-title>. <source>Mol Cancer Ther</source>. <year>2004</year>;<volume>3</volume>(<issue>3</issue>):<fpage>363</fpage>-<lpage>371</lpage>.<pub-id pub-id-type="pmid">15026557</pub-id></mixed-citation></ref><ref id="ref21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McFadyen</surname><given-names>MC</given-names></name><name name-style="western"><surname>Murray</surname><given-names>GI</given-names></name></person-group>. <article-title>Cytochrome P450 1B1: a novel anticancer therapeutic target</article-title>. <source>Future Oncol</source>. <year>2005</year>;<volume>1</volume>(<issue>2</issue>):<fpage>259</fpage>-<lpage>263</lpage>.<pub-id pub-id-type="pmid">16555997</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/14796694.1.2.259</pub-id></mixed-citation></ref><ref id="ref22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luby</surname><given-names>TM</given-names></name><name name-style="western"><surname>Cole</surname><given-names>G</given-names></name><name name-style="western"><surname>Baker</surname><given-names>L</given-names></name><name name-style="western"><surname>Kornher</surname><given-names>JS</given-names></name><name name-style="western"><surname>Ramstedt</surname><given-names>U</given-names></name><name name-style="western"><surname>Hedley</surname><given-names>ML</given-names></name></person-group>. <article-title>Repeated immunization with plasmid DNA formulated in poly(lactide-co-glycolide) microparticles is well tolerated and stimulates durable T cell responses to the tumor-associated antigen cytochrome P450 1B1</article-title>. <source>Clin Immunol</source>. <year>2004</year>;<volume>112</volume>(<issue>1</issue>):<fpage>45</fpage>-<lpage>53</lpage>.<pub-id pub-id-type="pmid">15207781</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clim.2004.04.002</pub-id></mixed-citation></ref><ref id="ref23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gribben</surname><given-names>JG</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>DP</given-names></name><name name-style="western"><surname>Boyajian</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy</article-title>. <source>Clin Cancer Res</source>. <year>2005</year>;<volume>11</volume>(<issue>12</issue>):<fpage>4430</fpage>-<lpage>4436</lpage>.<pub-id pub-id-type="pmid">15958627</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-04-2111</pub-id></mixed-citation></ref><ref id="ref24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rochat</surname><given-names>B</given-names></name><name name-style="western"><surname>Morsman</surname><given-names>JM</given-names></name><name name-style="western"><surname>Murray</surname><given-names>GI</given-names></name><name name-style="western"><surname>Figg</surname><given-names>WD</given-names></name><name name-style="western"><surname>McLeod</surname><given-names>HL</given-names></name></person-group>. <article-title>Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?</article-title><source>J Pharmacol Exp Ther</source>. <year>2001</year>;<volume>296</volume>(<issue>2</issue>):<fpage>537</fpage>-<lpage>541</lpage>.<pub-id pub-id-type="pmid">11160641</pub-id></mixed-citation></ref><ref id="ref25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chun</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name></person-group><article-title>Discovery of cytochrome P450 1B1 inhibitors as new promising anti-cancer agents</article-title>. <source>Med Res Rev</source>. <year>2003</year>;<volume>23</volume>(<issue>6</issue>):<fpage>657</fpage>-<lpage>668</lpage>.<pub-id pub-id-type="pmid">12939788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/med.10050</pub-id></mixed-citation></ref><ref id="ref26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spencer</surname><given-names>DL</given-names></name><name name-style="western"><surname>Masten</surname><given-names>SA</given-names></name><name name-style="western"><surname>Lanier</surname><given-names>KM</given-names></name><etal/></person-group>. <article-title>Quantitative analysis of constitutive and 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced cytochrome P450 1B1 expression in human lymphocytes</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source>. <year>1999</year>;<volume>8</volume>(<issue>2</issue>):<fpage>139</fpage>-<lpage>146</lpage>.<pub-id pub-id-type="pmid">10067811</pub-id></mixed-citation></ref><ref id="ref27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baron</surname><given-names>JM</given-names></name><name name-style="western"><surname>Zwadlo-Klarwasser</surname><given-names>G</given-names></name><name name-style="western"><surname>Jugert</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Cytochrome P450 1B1: a major P450 isoenzyme in human blood monocytes and macrophage subsets</article-title>. <source>Biochem Pharmacol</source>. <year>1998</year>;<volume>56</volume>(<issue>9</issue>):<fpage>1105</fpage>-<lpage>1110</lpage>.<pub-id pub-id-type="pmid">9802319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0006-2952(98)00105-1</pub-id></mixed-citation></ref><ref id="ref28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rentas</surname><given-names>S</given-names></name><name name-style="western"><surname>Holzapfel</surname><given-names>N</given-names></name><name name-style="western"><surname>Belew</surname><given-names>MS</given-names></name><etal/></person-group>. <article-title>Musashi-2 attenuates AHR signalling to expand human haematopoietic stem cells</article-title>. <source>Nature</source>. <year>2016</year>;<volume>532</volume>(<issue>7600</issue>):<fpage>508</fpage>-<lpage>511</lpage>.<pub-id pub-id-type="pmid">27121842</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature17665</pub-id><pub-id pub-id-type="pmcid">PMC4880456</pub-id></mixed-citation></ref><ref id="ref29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maecker</surname><given-names>B</given-names></name><name name-style="western"><surname>Sherr</surname><given-names>DH</given-names></name><name name-style="western"><surname>Vonderheide</surname><given-names>RH</given-names></name><etal/></person-group>. <article-title>The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells</article-title>. <source>Blood</source>. <year>2003</year>;<volume>102</volume>(<issue>9</issue>):<fpage>3287</fpage>-<lpage>3294</lpage>.<pub-id pub-id-type="pmid">12869499</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2003-05-1374</pub-id></mixed-citation></ref><ref id="ref30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagai</surname><given-names>F</given-names></name><name name-style="western"><surname>Hiyoshi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sugimachi</surname><given-names>K</given-names></name><name name-style="western"><surname>Tamura</surname><given-names>HO</given-names></name></person-group>. <article-title>Cytochrome P450 (CYP) expression in human myeloblastic and lymphoid cell lines</article-title>. <source>Biol Pharm Bull</source>. <year>2002</year>;<volume>25</volume>(<issue>3</issue>):<fpage>383</fpage>-<lpage>385</lpage>.<pub-id pub-id-type="pmid">11913539</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1248/bpb.25.383</pub-id></mixed-citation></ref><ref id="ref31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DiNardo</surname><given-names>CD</given-names></name><name name-style="western"><surname>Gharibyan</surname><given-names>V</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Impact of aberrant DNA methylation patterns including CYP1B1 methylation in adolescents and young adults with acute lymphocytic leukemia</article-title>. <source>Am J Hematol</source>. <year>2013</year>;<volume>88</volume>(<issue>9</issue>):<fpage>784</fpage>-<lpage>789</lpage>.<pub-id pub-id-type="pmid">23757320</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ajh.23511</pub-id><pub-id pub-id-type="pmcid">PMC3947930</pub-id></mixed-citation></ref><ref id="ref32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>DN</given-names></name><name name-style="western"><surname>Seidel</surname><given-names>A</given-names></name><name name-style="western"><surname>Pritchard</surname><given-names>MP</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>CR</given-names></name><name name-style="western"><surname>Friedberg</surname><given-names>T.</given-names></name></person-group><article-title>Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol</article-title>. <source>Pharmacogenetics</source>. <year>2000</year>;<volume>10</volume>(<issue>4</issue>):<fpage>343</fpage>-<lpage>353</lpage>.<pub-id pub-id-type="pmid">10862525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00008571-200006000-00008</pub-id></mixed-citation></ref><ref id="ref33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanna</surname><given-names>IH</given-names></name><name name-style="western"><surname>Dawling</surname><given-names>S</given-names></name><name name-style="western"><surname>Roodi</surname><given-names>N</given-names></name><name name-style="western"><surname>Guengerich</surname><given-names>FP</given-names></name><name name-style="western"><surname>Parl</surname><given-names>FF</given-names></name></person-group>. <article-title>Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity</article-title>. <source>Cancer Res</source>. <year>2000</year>;<volume>60</volume>(<issue>13</issue>):<fpage>3440</fpage>-<lpage>3444</lpage>.<pub-id pub-id-type="pmid">10910054</pub-id></mixed-citation></ref><ref id="ref34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gajjar</surname><given-names>K</given-names></name><name name-style="western"><surname>Martin-Hirsch</surname><given-names>PL</given-names></name><name name-style="western"><surname>Martin</surname><given-names>FL</given-names></name></person-group>. <article-title>CYP1B1 and hormone-induced cancer</article-title>. <source>Cancer Lett</source>. <year>2012</year>;<volume>324</volume>(<issue>1</issue>):<fpage>13</fpage>-<lpage>30</lpage>.<pub-id pub-id-type="pmid">22561558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.canlet.2012.04.021</pub-id></mixed-citation></ref><ref id="ref35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>JY</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>ZZ</given-names></name><name name-style="western"><surname>Xie</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Du</surname><given-names>YP</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name></person-group><article-title>Association between the CYP1B1 polymorphisms and risk of cancer: a meta-analysis</article-title>. <source>Mol Genet Genomics</source>. <year>2015</year>;<volume>290</volume>(<issue>2</issue>):<fpage>739</fpage>-<lpage>765</lpage>.<pub-id pub-id-type="pmid">25475389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00438-014-0946-x</pub-id></mixed-citation></ref><ref id="ref36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vineis</surname><given-names>P</given-names></name><name name-style="western"><surname>Veglia</surname><given-names>F</given-names></name><name name-style="western"><surname>Garte</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Genetic susceptibility according to three metabolic pathways in cancers of the lung and bladder and in myeloid leukemias in nonsmokers</article-title>. <source>Ann Oncol</source>. <year>2007</year>;<volume>18</volume>(<issue>7</issue>):<fpage>1230</fpage>-<lpage>1242</lpage>.<pub-id pub-id-type="pmid">17496311</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdm109</pub-id></mixed-citation></ref><ref id="ref37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ottinger</surname><given-names>HD</given-names></name><name name-style="western"><surname>Ferencik</surname><given-names>S</given-names></name><name name-style="western"><surname>Beelen</surname><given-names>DW</given-names></name><etal/></person-group>. <article-title>Hematopoietic stem cell transplantation: contrasting the outcome of transplantations from HLA-identical siblings, partially HLA-mismatched related donors, and HLA-matched unrelated donors</article-title>. <source>Blood</source>. <year>2003</year>;<volume>102</volume>(<issue>3</issue>):<fpage>1131</fpage>-<lpage>1137</lpage>.<pub-id pub-id-type="pmid">12689945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2002-09-2866</pub-id></mixed-citation></ref><ref id="ref38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elmaagacli</surname><given-names>AH</given-names></name><name name-style="western"><surname>Basoglu</surname><given-names>S</given-names></name><name name-style="western"><surname>Peceny</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia</article-title>. <source>Blood</source>. <year>2002</year>;<volume>99</volume>(<issue>4</issue>):<fpage>1130</fpage>-<lpage>1135</lpage>.<pub-id pub-id-type="pmid">11830457</pub-id></mixed-citation></ref><ref id="ref39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elmaagacli</surname><given-names>AH</given-names></name><name name-style="western"><surname>Peceny</surname><given-names>R</given-names></name><name name-style="western"><surname>Steckel</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Outcome of transplantation of highly purified peripheral blood CD34+ cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia</article-title>. <source>Blood</source>. <year>2003</year>;<volume>101</volume>(<issue>2</issue>):<fpage>446</fpage>-<lpage>453</lpage>.<pub-id pub-id-type="pmid">12393406</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2002-05-1615</pub-id></mixed-citation></ref><ref id="ref40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>ED</given-names></name><name name-style="western"><surname>Storb</surname><given-names>R</given-names></name><name name-style="western"><surname>Clift</surname><given-names>RA</given-names></name><etal/></person-group>. <article-title>Bone-marrow transplantation (second of two parts)</article-title>. <source>N Engl J Med</source>. <year>1975</year>;<volume>292</volume>(<issue>17</issue>):<fpage>895</fpage>-<lpage>902</lpage>.<pub-id pub-id-type="pmid">235092</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM197504242921706</pub-id></mixed-citation></ref><ref id="ref41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Przepiorka</surname><given-names>D</given-names></name><name name-style="western"><surname>Weisdorf</surname><given-names>D</given-names></name><name name-style="western"><surname>Martin</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>1994 Consensus Conference on Acute GVHD Grading</article-title>. <source>Bone Marrow Transplant</source>. <year>1995</year>;<volume>15</volume>(<issue>6</issue>):<fpage>825</fpage>-<lpage>828</lpage>.<pub-id pub-id-type="pmid">7581076</pub-id></mixed-citation></ref><ref id="ref42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shulman</surname><given-names>HM</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>KM</given-names></name><name name-style="western"><surname>Weiden</surname><given-names>PL</given-names></name><etal/></person-group>. <article-title>Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients</article-title>. <source>Am J Med</source>. <year>1980</year>;<volume>69</volume>(<issue>2</issue>):<fpage>204</fpage>-<lpage>217</lpage>.<pub-id pub-id-type="pmid">6996481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0002-9343(80)90380-0</pub-id></mixed-citation></ref><ref id="ref43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maniatis</surname><given-names>T</given-names></name><name name-style="western"><surname>Fritsch</surname><given-names>EF</given-names></name><name name-style="western"><surname>Sambrook</surname><given-names>J.</given-names></name></person-group><article-title>Molecular Cloning</article-title>. <source>A Laboratory Manual. Cold Spring Harbor Laboratory Press</source>. <year>1982</year>.</mixed-citation></ref><ref id="ref44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruning</surname><given-names>T</given-names></name><name name-style="western"><surname>Abel</surname><given-names>J</given-names></name><name name-style="western"><surname>Koch</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Real-time PCR-analysis of the cytochrome P450 1B1 codon 432-polymorphism</article-title>. <source>Arch Toxicol</source>. <year>1999</year>;<volume>73</volume>(<issue>8-9</issue>):<fpage>427</fpage>-<lpage>430</lpage>.<pub-id pub-id-type="pmid">10650913</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s002040050631</pub-id></mixed-citation></ref><ref id="ref45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaplan</surname><given-names>EL</given-names></name><name name-style="western"><surname>Meier</surname><given-names>P.</given-names></name></person-group><article-title>Non-parametric estimation from incomplete observations</article-title>. <source>J Am Stat Assoc</source>. <year>1958</year>;<volume>53</volume>(<issue>282</issue>):<fpage>457</fpage>-<lpage>481</lpage>.</mixed-citation></ref><ref id="ref46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cox</surname><given-names>DR</given-names></name></person-group>. <article-title>Regression models and life-tables</article-title>. <source>J R Stat Soc Ser B</source>. <year>1972</year>;<volume>34</volume>(<issue>2</issue>):<fpage>187</fpage>-<lpage>220</lpage>.</mixed-citation></ref><ref id="ref47"><label>47.</label><mixed-citation publication-type="journal"><collab>R Core Team</collab>. <article-title>R: A Language and Environment for Statistical Computing</article-title>. <source>R Foundation for Statistical Computing</source>. <year>2018</year>.</mixed-citation></ref><ref id="ref48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iacobelli</surname><given-names>S</given-names></name><name name-style="western"><surname>EBMT</surname><given-names>Statistical Committee</given-names></name></person-group>. <article-title>Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation</article-title>. <source>Bone Marrow Transplant</source>. <year>2013</year>;<volume>48</volume>(<issue>Suppl 1</issue>):<fpage>S1</fpage>-<lpage>37</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/bmt.2012.282</pub-id><pub-id pub-id-type="pmid">23462821</pub-id></mixed-citation></ref><ref id="ref49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>RStudio</surname><given-names>Team</given-names></name></person-group>. <article-title>RStudio: Integrated Development Environment for R</article-title>. <source>RStudio, Inc</source>. <year>2015</year>.</mixed-citation></ref><ref id="ref50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fritsche</surname><given-names>E</given-names></name><name name-style="western"><surname>Bruning</surname><given-names>T</given-names></name><name name-style="western"><surname>Jonkmanns</surname><given-names>C</given-names></name><name name-style="western"><surname>Ko</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bolt</surname><given-names>HM</given-names></name><name name-style="western"><surname>Abel</surname><given-names>J.</given-names></name></person-group><article-title>Detection of cytochrome P450 1B1 Bfr I polymorphism: genotype distribution in healthy German individuals and in patients with colorectal carcinoma</article-title>. <source>Pharmacogenetics</source>. <year>1999</year>;<volume>9</volume>(<issue>3</issue>):<fpage>405</fpage>-<lpage>408</lpage>.<pub-id pub-id-type="pmid">10471075</pub-id></mixed-citation></ref><ref id="ref51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>YM</given-names></name><name name-style="western"><surname>Green</surname><given-names>BL</given-names></name><name name-style="western"><surname>Chen</surname><given-names>GF</given-names></name><etal/></person-group>. <article-title>Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls</article-title>. <source>Pharmacogenetics</source>. <year>2000</year>;<volume>10</volume>(<issue>9</issue>):<fpage>761</fpage>-<lpage>766</lpage>.<pub-id pub-id-type="pmid">11221602</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00008571-200012000-00001</pub-id></mixed-citation></ref><ref id="ref52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sissung</surname><given-names>TM</given-names></name><name name-style="western"><surname>Danesi</surname><given-names>R</given-names></name><name name-style="western"><surname>Price</surname><given-names>DK</given-names></name><etal/></person-group>. <article-title>Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel</article-title>. <source>Mol Cancer Ther</source>. <year>2008</year>;<volume>7</volume>(<issue>1</issue>):<fpage>19</fpage>-<lpage>26</lpage>.<pub-id pub-id-type="pmid">18187806</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1535-7163.MCT-07-0557</pub-id></mixed-citation></ref><ref id="ref53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loren</surname><given-names>AW</given-names></name><name name-style="western"><surname>Bunin</surname><given-names>GR</given-names></name><name name-style="western"><surname>Boudreau</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation</article-title>. <source>Biol Blood Marrow Transplant</source>. <year>2006</year>;<volume>12</volume>(<issue>7</issue>):<fpage>758</fpage>-<lpage>769</lpage>.<pub-id pub-id-type="pmid">16785065</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbmt.2006.03.015</pub-id></mixed-citation></ref><ref id="ref54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gahrton</surname><given-names>G</given-names></name></person-group>. <article-title>Risk assessment in haematopoietic stem cell transplantation: impact of donor-recipient sex combination in allogeneic transplantation</article-title>. <source>Best Pract Res Clin Haematol</source>. <year>2007</year>;<volume>20</volume>(<issue>2</issue>):<fpage>219</fpage>-<lpage>229</lpage>.<pub-id pub-id-type="pmid">17448958</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.beha.2006.09.007</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>